TICKERNERD
Menu
EVMNEVMNHealthcare · Biotechnology

EVMN Stock Forecast: Evommune, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$6.41
+3.05% on the day

The 11 Wall Street analysts covering Evommune, Inc. hold a median 12-month price target of $24 — +274.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$232.6M
Ticker Nerd rank
10 / 100
Median analyst target
$24
Analysts covering
11
Revenue$0.0
Operating income−$34.9M
Net income−$32.2M
Free cash flow−$20.5M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.1%
1M
−51.0%
YTD
−62.6%
From high
−79.7%
From low
+3.1%
$6
$32
Range since 6 Nov 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

EVMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evommune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
66
Issuance
64
Quality
48
Revisions
28
Value
27
Accruals
26
Growth
8
Volatility
4
Momentum
0

Size (66): Smaller than most of the companies we track.

Momentum (0): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EVMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Nov 2025Adjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26EVMNHigh $30Median $24Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $18Median $24High $30

The green dot is the last close — the median target sits +274.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
9 Sept 2026HC Wainwright & Co.ReiteratesNeutral—
9 Sept 2026Leerink PartnersMaintainsOutperform$28 → $22
9 Sept 2026RBC CapitalMaintainsOutperform$29 → $21
26 Aug 2026NeedhamInitiatesBuy$28
26 Aug 2026NeedhamInitiatesBuy—
7 Aug 2026RBC CapitalMaintainsOutperform$30 → $29
7 Aug 2026RBC CapitalMaintainsOutperform—
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
30 June 2026HC Wainwright & Co.DowngradeNeutral—
30 June 2026HC Wainwright & Co.DowngradeNeutral—
30 June 2026Morgan StanleyMaintainsOverweight—
30 June 2026Morgan StanleyMaintainsOverweight$55 → $26
29 June 2026William BlairDowngradeMarket Perform—
29 June 2026William BlairDowngradeMarket Perform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026Morgan StanleyMaintainsOverweight—
10 Apr 2026RBC CapitalReiteratesOutperform—
18 Mar 2026Clear StreetInitiatesBuy—
18 Mar 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVMN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EVMN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

EVMN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26EVMNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EVMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Evommune, Inc. (EVMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
23.3×

Cheaper than 8% of US stocks

Price / book
0.8×

Cheaper than 76% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1018.9%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.1%

Higher than 21% of US stocks

Return on assets
−32.0%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Evommune, Inc. (EVMN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evommune, Inc. has a market value of $232.6M and an enterprise value of $33.6M.

  • Revenue in the twelve months to 30 June 2026: $10.0M.

  • Net income over the same four quarters: −$94.7M, a −946.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.37.

  • Free cash flow in the twelve months to 30 June 2026: −$74.7M.

  • Shares outstanding: 36.3M.

  • Trailing P/E: −0.6×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Evommune, Inc. employs 48 people — $208K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

EVMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EVMNEvommune, Inc.$232.6M
10
NAUTNautilus Biotechnology, Inc.$231.3M
60
SLGLSol-Gel Technologies Ltd.$229.9M
45
CAMPCAMP4 Therapeutics Corp.$232.2M
61
KROSKeros Therapeutics, Inc.$229.5M
71
MGNXMacroGenics, Inc.$225.6M
65
IFRXInflaRx NV$225.4M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Evommune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EVMN news & analysis

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Business Wire · 1 Oct 2026positive

Evommune presented additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking oral presentation at the European Academy of Dermatology and Venereology 2026 Congress in Vienna. The data were shared by the clinical-stage biotechnology company developing therapies targeting key drivers of chronic inflammatory diseases.

Why it matters — This presentation highlights progress with EVO301, a lead investigational candidate, providing EVMN watchers with new clinical data on a potential treatment for atopic dermatitis.

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

Business Wire · 23 Sept 2026positive

Evommune, Inc. announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress in Vienna, Austria. The company is a clinical-stage biotechnology firm developing therapies targeting chronic inflammatory diseases.

Why it matters — A late-breaking oral presentation at a major dermatology congress highlights the company's pipeline progress and brings EVO301's Phase 2a data to the attention of a broad dermatology audience.

Evommune Halts Atopic Dermatitis Program Following Trial Failure

Benzinga · 9 Sept 2026negative

Evommune announced topline results from its Phase 2b dose-ranging trial of oral EVO756 for moderate-to-severe atopic dermatitis, which did not meet expectations, leading the company to halt its atopic dermatitis program.

Why it matters — The discontinuation of the EVO756 atopic dermatitis program removes a key pipeline candidate for the clinical-stage company, affecting its development roadmap.

Evommune scraps eczema drug after trial miss, shares plunge

Reuters · 8 Sept 2026negative

Evommune announced it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.

Why it matters — The discontinuation of a lead pipeline candidate and the resulting 24% share decline represents a significant setback for Evommune's development prospects.

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Business Wire · 8 Sept 2026neutral

Evommune announced top-line results from its randomized, double-blind, placebo-controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of its oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The announcement provides initial data from this clinical study of the company's developmental therapy.

Why it matters — Phase 2b data for EVO756 is a key clinical milestone for Evommune's pipeline in chronic inflammatory disease, informing investors about the therapy's efficacy and safety profile.

FAQ

Frequently asked questions about EVMN stock

What is the EVMN stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Evommune, Inc. have a median 12-month price target of $24, with estimates ranging from $18 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EVMN stock a buy right now?

Of the 11 analysts covering Evommune, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evommune, Inc. 10 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EVMN?

As at 8 Oct 2026, Evommune, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (66 of 100).

Will EVMN stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +274.4% from the last close, and Ticker Nerd's factor model ranks Evommune, Inc. 10 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EVMN stock forecast for 2030?

No analyst covering Evommune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $30 over the next 12 months.

What does Evommune, Inc. do?

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases.

What is the latest news on EVMN?

The most recent item we track (Business Wire, 1 Oct 2026): "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". Evommune presented additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking oral presentation at the European Academy of Dermatology and Venereology 2026 Congress in Vienna. The data were shared by the clinical-stage biotechnology company developing therapies targeting key drivers of chronic inflammatory diseases.

Company

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing novel treatments designed to address key drivers of inflammation, with current programs centered on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline includes product candidates such as EVO756 and EVO301, which are being developed to target immune pathways involved in these conditions. Evommune’s work is positioned within the broader immunology and inflammation markets, where it aims to support more precise treatment options for patients with persistent inflammatory disorders. Based in Palo Alto, California, Evommune emphasizes research-driven drug development across small-molecule and biologic approaches.

CEO Mr. Luis C. Pena · 48 employees · United States · https://www.evommune.com